| Name | Title | Contact Details |
|---|
Every day, in everything we do, our purpose is to protect, heal and nurture in the relentless pursuit of a cleaner, healthier world. And we have a fight on our hands. A fight to make access to the highest quality hygiene, wellness and nourishment a right and not a privilege. Each of our products is designed to do exactly this. Our well-loved brands have been making a difference to people`s daily lives around the world for more than 200 years. Brands including: Durex, Dettol, Enfamil, Nurofen, Strepsils, Gaviscon, Mucinex, Nutramigen, Lysol, Harpic, Cillit Bang, Finish and Vanish. By 2030, our ambition is to reach half of the world, every year. We`re a growing global community of over 43,000 people on a journey of transformation and sustainable growth. Together, our success will continue to positively impact communities everywhere, for a healthier planet and a fairer society.
Edinburgh Imports Inc is a Woodland Hills, CA-based company in the Consumer Services sector.
TFMComm is a Topeka, KS-based company in the Consumer Services sector.
Flamel Technologies SA is a specialty pharmaceutical company utilizing its core competencies in formulation development and drug delivery to develop safer and more efficacious pharmaceutical products, addressing unmet medical needs and/or reducing overall healthcare costs. Flamel currently has approvals for and markets two previously Unapproved Marketed Drugs ("UMDs") in the USA, Bloxiverz® (neostigmine methylsulfate injection) and Vazculep® (phenylephrine hydrochloride injection). The Company intends to add to this branded business by creating additional products, focusing on the development of products utilizing Flamel`s proprietary drug delivery platforms, and recently announced FDA acceptance of its third NDA filing with an FDA-assigned PDUFA date of April 30, 2016. Flamel also has several products in development utilizing Micropump® (oral sustained release microparticles platform) along with its tangent technologies, LiquiTime® and Trigger Lock™. The lead project for Micropump® is sodium oxybate. LiquiTime® allows for the extended-release of liquid medicines (such as ibuprofen and guaifenesin) and Trigger Lock™ is an abuse-resistant iteration of Micropump®, designed specifically for long-acting opioids (such as hydromorphone). Additionally, the Company has developed a long acting injectable platform, Medusa™, a hydrogel depot technology currently being studied with exenatide. Flamel`s products are targeting high-value molecules and will utilize either the 505(b)(2) approval process for NDAs or biosimilar pathways ultimately approved by FDA and other regulatory authorities. The Company is headquartered in Lyon, France and has operations in St. Louis, Missouri, USA, and Dublin, Ireland.
Deyo Inc is a Jacksonville, FL-based company in the Consumer Services sector.